[Form 4] Charles River Laboratories International, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Joseph W. LaPlume, an officer and director at Charles River Laboratories (CRL) serving as EVP, Corporate Strategy & Development, reported an open-market sale of 800 shares of CRL common stock on 08/18/2025 at a reported price of $157.60 per share. After the transaction he beneficially owned 24,116 shares. The Form 4 was signed on 08/20/2025. The filing discloses a single non-derivative sale and no derivatives or additional transactions.

Positive

• None.

Negative

• Insider sale reported: Officer/director sold 800 shares at $157.60, reducing holdings to 24,116 shares.

Insights

Financial Analyst

TL;DR: Insider sold a small block of shares; transaction appears routine and provides limited new information for valuation.

The sale of 800 shares at $157.60 reduced the reporting person’s holdings to 24,116 shares. The filing contains only a single non-derivative sale and no derivative activity. Without additional context on pre-existing plans, size relative to total holdings, or timing rationale, this transaction is a routine disclosure and is unlikely to materially change the company’s financial outlook.

Corporate Governance Expert

TL;DR: Officer/director sale documented properly on Form 4; disclosure meets Section 16 requirements.

The Form 4 indicates the reporting person is both an officer and director and shows the required signature and dates. The report lists the transaction code for a sale and specifies direct ownership. The filing contains no indication of Rule 10b5-1 plan or other exemptions. From a governance and compliance perspective, the document appears complete for the disclosed transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaPlume Joseph W

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MA 01887

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Corp Strategy & Develop

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S		800	D	$157.6	24,116	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Joseph W. LaPlume	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joseph W. LaPlume report on the Form 4 for CRL?

The Form 4 reports a non-derivative sale of 800 shares of CRL common stock on 08/18/2025 at $157.60, leaving 24,116 shares beneficially owned.

What is Joseph W. LaPlume's role at Charles River Laboratories (CRL)?

He is reported as an officer and director, with the title EVP, Corporate Strategy & Development.

When was the Form 4 for this transaction signed?

The Form 4 bears the reporting person’s signature dated 08/20/2025.

Does the filing show any derivative transactions or 10b5-1 plan?

No. The filing discloses only a single non-derivative sale and contains no indication of derivative activity or a Rule 10b5-1 written plan.